Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Gastric Cancer
Published in: Gastric Cancer 1/2012

01-01-2012 | Original article

Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer

Authors: Hiroaki Saito, Tomohiro Osaki, Masahide Ikeguchi

Published in: Gastric Cancer | Issue 1/2012

Login to get access

Abstract

Background

Although malignant diseases are known to be associated with immune suppression, the detailed mechanisms involved are still unknown. NKG2D is an activating cell surface receptor expressed by natural killer (NK) cells and CD8+ T cells, and the engagement of NKG2D is extremely important for NK cell activation. Although decreased NKG2D expression on NK cells is closely related to immune evasion by some cancers, the immunopathological importance of this phenomenon in gastric cancer patients remains unclear.

Methods

NKG2D expression on NK cells was determined, using multicolor flow cytometry, to investigate the mechanisms responsible for immune evasion in gastric cancer patients.

Results

NKG2D expression on NK cells from gastric cancer patients was significantly lower than that in healthy controls. Also, NKG2D expression in advanced gastric cancer was significantly lower than that in early gastric cancer. NK cells from patients with lymph node metastasis expressed significantly lower levels of NKG2D than the NK cells from those without lymph node metastasis, and NKG2D expression on NK cells in gastric cancer tissue was significantly lower than that of circulating NK cells. NKG2D expression on NK cells obtained from cancer patients was restored after 48 h in culture with RPMI containing 10% AB serum. Furthermore, NKG2D expression on NK cells obtained after surgery was significantly higher than that before surgery.

Conclusions

Decreased NKG2D expression on NK cells may be one of the key mechanisms responsible for NK cell dysfunction in gastric cancer.
Literature
1.
2.
Tsutsui S, Morita M, Kuwano H, Matsuda H, Mori M, Okamura S, et al. Influence of preoperative treatment and surgical operation on immune function of patients with esophageal carcinoma. J Surg Oncol. 1992;49:176–81.PubMedCrossRef
3.
Nunn ME, Herberman RB. Natural cytotoxicity of mouse, rat, and human lymphocytes against heterologous target cells. J Natl Cancer Inst. 1979;62:765–71.PubMed
4.
Vose BM, Moore M. Natural cytotoxicity in humans: susceptibility of freshly isolated tumor cells to lysis. J Natl Cancer Inst. 1980;65:257–63.PubMed
5.
Uchida A, Yanagawa E. Natural killer cell activity and autologous tumor killing activity in cancer patients: overlapping involvement of effector cells as determined in two-target conjugate cytotoxicity assay. J Natl Cancer Inst. 1984;73:1093–100.PubMed
6.
Vujanovic NL, Herberman RB, Maghazachi AA, Hiserodt JC. Lymphokine-activated killer cells in rats, III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells. J Exp Med. 1988;167:15–29.PubMedCrossRef
7.
Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse, I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5:112–7.PubMedCrossRef
8.
Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors, I. Distribution of reactivity and specificity. Int J Cancer. 1975;16:216–29.PubMedCrossRef
9.
Ames IH, Garcia AM, John PA, Litty CA, Farrell MA, Tomar RH. Decreased natural cytotoxicity in mice with high incidence of mammary adenocarcinoma. Clin Immunol Immunopathol. 1986;38:265–73.PubMedCrossRef
10.
Cook JL, Lewis AM Jr. Immunological surveillance against DNA-virus-transformed cells: correlations between natural killer cell cytolytic competence and tumor susceptibility of athymic rodents. J Virol. 1987;61:2155–61.PubMed
11.
Talmadge JE, Meyers KM, Prieur DJ, Starkey JR. Role of NK cells in tumour growth and metastasis in beige mice. Nature. 1980;284:622–4.PubMedCrossRef
12.
Hanna N, Burton RC. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. J Immunol. 1981;127:1754–8.PubMed
13.
Barlozzari T, Leonhardt J, Wiltrout RH, Herberman RB, Reynolds CW. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol. 1985;134:2783–9.PubMed
14.
Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356:1795–9.PubMedCrossRef
15.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef
16.
Takahashi A, Kono K, Amemiya H, Iizuka H, Fujii H, Matsumoto Y. Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apoptosis and down-regulation of TCR zeta molecules in patients with gastric cancer. Clin Cancer Res. 2001;7:74–80.PubMed
17.
Osaki T, Saito H, Yoshikawa T, Matsumoto S, Tatebe S, Tsujitani S, et al. Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res. 2007;13:382–7.PubMedCrossRef
18.
Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+ CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer. 2003;98:1089–99.PubMedCrossRef
19.
Oka M, Mitsunaga H, Hazama S, Yoshino S, Suzuki T. Natural killer activity and serum immunosuppressive acidic protein levels in esophageal and gastric cancers. Surg Today. 1993;23:669–74.PubMedCrossRef
20.
Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am J Gastroenterol. 2001;96:574–8.
21.
Glienke J, Sobanov Y, Brostjan C, Steffens C, Nguyen C, Lehrach H, et al. The genomic organization of NKG2C, E, F, and D receptor genes in the human natural killer gene complex. Immunogenetics. 1998;48:163–73.PubMedCrossRef
22.
23.
Watzl C. The NKG2D receptor and its ligands–recognition beyond the “missing self”? Microbes Infect. 2003;5:31–7.PubMedCrossRef
24.
Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr Opin Immunol. 2002;14:306–11.PubMedCrossRef
25.
Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727–9.PubMedCrossRef
26.
Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419:734–8.PubMedCrossRef
27.
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer. 1998;1:10–24.PubMedCrossRef
28.
Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest. 2004;114:560–8.PubMed
29.
Yokoyama WM, Plougastel BF. Immune functions encoded by the natural killer gene complex. Nat Rev Immunol. 2003;3:304–16.PubMedCrossRef
30.
Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5:201–14.PubMedCrossRef
31.
Ruggeri L, Aversa F, Martelli MF, Velardi A. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev. 2006;214:202–18.PubMedCrossRef
32.
Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, Moretta L, et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res. 2004;64:9180–4.PubMedCrossRef
33.
Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004;114:379–88.PubMed
34.
Shen YQ, Zhang JQ, Miao FQ, Zhang JM, Jiang Q, Chen H, et al. Relationship between the downregulation of HLA class I antigen and clinicopathological significance in gastric cancer. World J Gastroenterol. 2005;11:3628–31.PubMed
35.
Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123–33.PubMedCrossRef
36.
Chalupny NJ, Sutherland CL, Lawrence WA, Rein-Weston A, Cosman D. ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun. 2003;305:129–35.PubMedCrossRef
37.
Conejo-Garcia JR, Benencia F, Courreges MC, Khang E, Zhang L, Mohamed-Hadley A, et al. Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol Ther. 2003;2:446–51.PubMed
38.
Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008;28:571–80.PubMedCrossRef
39.
Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102:1389–96.PubMedCrossRef
40.
Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O’Reilly RJ, Dupont B, et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol. 2003;171:6891–9.PubMed
41.
Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci USA. 2006;103:9190–5.PubMedCrossRef
42.
Murakami S, Okubo K, Tsuji Y, Sakata H, Hamada S, Hirayama R. Serum interleukin-12 levels in patients with gastric cancer. Surg Today. 2004;34:1014–9.PubMedCrossRef
Metadata
Title
Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer
Authors
Hiroaki Saito
Tomohiro Osaki
Masahide Ikeguchi
Publication date
01-01-2012
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 1/2012
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-011-0059-8

Other articles of this Issue 1/2012

Gastric Cancer 1/2012 Go to the issue

Original article

Multicenter study of the long-term outcomes of endoscopic submucosal dissection for early gastric cancer in patients 80 years of age or older

Original article

Usefulness of enhanced recovery after surgery protocol as compared with conventional perioperative care in gastric surgery

Original article

Survival benefit of bursectomy in patients with resectable gastric cancer: interim analysis results of a randomized controlled trial

Original article

Clinical validity of endoscopic submucosal dissection for submucosal invasive gastric cancer: a single-center study

Original article

Discrepancies in histologic diagnoses of early gastric cancer between biopsy and endoscopic mucosal resection specimens

Original article

A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits